Dow Jones
37.753,31 -45,66 (-0,12%) Nasdaq
15.683,37 -181,88 (-1,15%) Nikkei 225
38.060,67 +98,87 (+0,26%) EUR/USD
1,0692 +0,0017 (+0,16%) Bitcoin EUR
57.243,35 -2.542,18 (-4,25%) CMC Crypto 200
885,54 0,00 (0,00%)
Biocartis Group NV (0R72.L)
| Chiusura precedente | 1,7197 |
| Aperto | 1,7197 |
| Denaro | N/D x N/D |
| Lettera | N/D x N/D |
| Min-Max giorno | 1,7200 - 1,7200 |
| Intervallo di 52 settimane | 0,2865 - 1,7200 |
| Volume | |
| Media Volume | 74.375 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 1,29 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswirePress release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio
PRESS RELEASE 16 October 2023, 7:00 CEST Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio Mechelen, Belgium, 16 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company, announces the launch of the new Breast Cancer Portfolio during the Breast Cancer Awareness month: the Idylla™ PIK3CA-AKT1 Mutation Assay and, in collaboration with APIS Assay Technologies (‘APIS’), the APIS Breast Cancer Subtyping Kit and t
- GlobeNewswire
Press release Biocartis Group NV: Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit
PRESS RELEASE 12 October 2023, 7:00 CEST Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit Mechelen, Belgium, 12 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company and APIS Assay Technologies Ltd. (‘APIS’), a private UK based company specializing in molecular diagnostics, today announced the expansion of their partnership1 to include the commercialization of the A
- GlobeNewswire
Press Release Biocartis Group NV: Disclosure of transparency notification
PRESS RELEASE: REGULATED INFORMATION 3 October 2023, 7:00 CEST Disclosure of transparency notification Mechelen, Belgium, 3 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down miscellaneous p
